Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Medmira Inc V.MIR

Alternate Symbol(s):  MMIRF

Healthcare Biotechnology
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The majority of the revenue is generated from North America.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSXV:MIR)

Fundamentals Snapshot (TSXV:MIR)

Current News (TSXV:MIR)

MedMira Reports Second Quarter Results FY2023

Accesswire April 3, 2023

Update on MedMira's Reveal TP (Syphilis) Clinical Trials in Canada

Accesswire March 14, 2023

Tracking growth: The SARS CoV 2 antigen test kit market

Jon Brown February 27, 2023

Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis

Business Wire February 20, 2023

MedMira Enters into Partnership with Maternova for USA and Latin America

Accesswire February 20, 2023

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

Accesswire January 11, 2023

Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)

Accesswire January 3, 2023

MedMira Reports First Quarter Results FY2023

Accesswire December 30, 2022

MedMira Introduces VYRA TriDemic

Accesswire December 29, 2022
View More News ››

Opinion & Analysis (TSXV:MIR)

Buzz on the Bullboards: A Fresh Start for Capital Markets in 2021?

Stockhouse Editorial January 7, 2021

Buzz on the Bullboards: New Coronavirus Testing Developments

Omri Wallach May 28, 2020

Buzz on the Bullboards: COVID-19 Testing Plays

Omri Wallach May 7, 2020

Buzz on the Bullboards: Who’s Hot In All Sectors

Omri Wallach April 30, 2020
View More Opinion ››

Bullboard Posts (TSXV:MIR)

JUNE 2023 UPDATES

NO UPDATES TO DATE. AT THIS POINT ANY APPROVAL FROM BIG BROTHER FOR APPLICATION OF 30-12-2020 MIGHT NOT BRING ANY IMPACT ON QUARTERLY...
august202013 - 2 days ago

RE:Inability to make any changes

Wharfy, I would never assess you folks as "fools". The only clown and fool is the CFO. 
Petey78 - 4 days ago

RE:Inability to make any changes

Correct CANNOT improve BIG BROTHER approval process that is PRECISELY The point. WHAT the new BOARD going to IMPRESS upon the MAJORITY...
august202013 - 11 days ago

Inability to make any changes

Although they suggest that minority shareholders (less than the 70%) might have some influence, we probably do not. How can we improve...
waverleywharf - 11 days ago

STRATEGY TO CONSIDER

Monitor next 2 Quarterly FINANCIAL STATEMENTS MINUS ANY BIG Brother's APPROVAL .  If small deficit then can SERIOUSLY consider...
august202013 - 11 days ago

RE:RE:DEPRESSING BUT HANG ON FOR JUMPSTART

3rd Quarterly ending 30 April 2023 due by 1st week of July, 2023.
august202013 - 13 days ago
View more Bullboard ››

Eloro Resources Ltd

Eloro Resources Ltd

Eloro is an exploration and mine development company with a portfolio of gold and base metal properties in Bolivia, Peru, and ...
View More »